General MedicationsINJECTIONGeneric

PIPERACILLIN AND TAZOBACTAM

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Standard Dose

EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview PIPERACILLIN AND TAZOBACTAM is listed in Drugs@FDA under application 212287 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Sponsor ASTRAL Submission history Latest submission status date: 2022-06-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview PIPERACILLIN AND TAZOBACTAM is listed in Drugs@FDA under application 212287 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Sponsor ASTRAL Submission history Latest submission status date: 2022-06-22 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.